These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

523 related articles for article (PubMed ID: 29036500)

  • 21. Integrated analysis of genetic and epigenetic alterations reveals CpG island methylator phenotype associated with distinct clinical characters of lung adenocarcinoma.
    Shinjo K; Okamoto Y; An B; Yokoyama T; Takeuchi I; Fujii M; Osada H; Usami N; Hasegawa Y; Ito H; Hida T; Fujimoto N; Kishimoto T; Sekido Y; Kondo Y
    Carcinogenesis; 2012 Jul; 33(7):1277-85. PubMed ID: 22532250
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metabologenomic characterization uncovers a clinically aggressive IDH mutant glioma subtype.
    Nassiri F; Ajisebutu A; Patil V; Mamatjan Y; Liu J; Wang JZ; Voisin MR; Nejad R; Mansouri S; Karimi S; Chakravarthy A; Chen E; De Carvalho DD; Aldape K; Zadeh G
    Acta Neuropathol; 2024 Apr; 147(1):68. PubMed ID: 38583102
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The CpG island methylator phenotype: what's in a name?
    Hughes LA; Melotte V; de Schrijver J; de Maat M; Smit VT; Bovée JV; French PJ; van den Brandt PA; Schouten LJ; de Meyer T; van Criekinge W; Ahuja N; Herman JG; Weijenberg MP; van Engeland M
    Cancer Res; 2013 Oct; 73(19):5858-68. PubMed ID: 23801749
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CpG island methylator phenotype infers a poor disease-free survival in locally advanced rectal cancer.
    Jo P; Jung K; Grade M; Conradi LC; Wolff HA; Kitz J; Becker H; Rüschoff J; Hartmann A; Beissbarth T; Müller-Dornieden A; Ghadimi M; Schneider-Stock R; Gaedcke J
    Surgery; 2012 Apr; 151(4):564-70. PubMed ID: 22001634
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MethylMeter(®): bisulfite-free quantitative and sensitive DNA methylation profiling and mutation detection in FFPE samples.
    McCarthy D; Pulverer W; Weinhaeusel A; Diago OR; Hogan DJ; Ostertag D; Hanna MM
    Epigenomics; 2016 Jun; 8(6):747-65. PubMed ID: 27337298
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The CpG island methylator phenotype correlates with long-range epigenetic silencing in colorectal cancer.
    Karpinski P; Ramsey D; Grzebieniak Z; Sasiadek MM; Blin N
    Mol Cancer Res; 2008 Apr; 6(4):585-91. PubMed ID: 18403637
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Integrative analysis identifies an immune-relevant epigenetic signature for prognostication of non-G-CIMP glioblastomas.
    Yin A; Shang Z; Etcheverry A; He Y; Aubry M; Lu N; Liu Y; Mosser J; Lin W; Zhang X; Dong Y
    Oncoimmunology; 2021 Mar; 10(1):1902071. PubMed ID: 33854822
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CpG island methylator phenotype (CIMP) in cancer: causes and implications.
    Teodoridis JM; Hardie C; Brown R
    Cancer Lett; 2008 Sep; 268(2):177-86. PubMed ID: 18471961
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic, epigenetic, and clinicopathologic features of gastric carcinomas with the CpG island methylator phenotype and an association with Epstein-Barr virus.
    Kusano M; Toyota M; Suzuki H; Akino K; Aoki F; Fujita M; Hosokawa M; Shinomura Y; Imai K; Tokino T
    Cancer; 2006 Apr; 106(7):1467-79. PubMed ID: 16518809
    [TBL] [Abstract][Full Text] [Related]  

  • 30. c-Jun-N-terminal phosphorylation regulates DNMT1 expression and genome wide methylation in gliomas.
    Heiland DH; Ferrarese R; Claus R; Dai F; Masilamani AP; Kling E; Weyerbrock A; Kling T; Nelander S; Carro MS
    Oncotarget; 2017 Jan; 8(4):6940-6954. PubMed ID: 28036297
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CpG Island Methylator Phenotype-High Colorectal Cancers and Their Prognostic Implications and Relationships with the Serrated Neoplasia Pathway.
    Rhee YY; Kim KJ; Kang GH
    Gut Liver; 2017 Jan; 11(1):38-46. PubMed ID: 27885175
    [TBL] [Abstract][Full Text] [Related]  

  • 32. No association of CpG island methylator phenotype and colorectal cancer survival: population-based study.
    Jia M; Jansen L; Walter V; Tagscherer K; Roth W; Herpel E; Kloor M; Bläker H; Chang-Claude J; Brenner H; Hoffmeister M
    Br J Cancer; 2016 Nov; 115(11):1359-1366. PubMed ID: 27811854
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Unraveling the glioma epigenome: from molecular mechanisms to novel biomarkers and therapeutic targets.
    Malzkorn B; Wolter M; Riemenschneider MJ; Reifenberger G
    Brain Pathol; 2011 Nov; 21(6):619-32. PubMed ID: 21939466
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular subclassification of diffuse gliomas: seeing order in the chaos.
    Huse JT; Phillips HS; Brennan CW
    Glia; 2011 Aug; 59(8):1190-9. PubMed ID: 21446051
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epigenetic alterations in colorectal cancer: the CpG island methylator phenotype.
    Bae JM; Kim JH; Kang GH
    Histol Histopathol; 2013 May; 28(5):585-95. PubMed ID: 23341177
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pan-cancer stratification of solid human epithelial tumors and cancer cell lines reveals commonalities and tissue-specific features of the CpG island methylator phenotype.
    Sánchez-Vega F; Gotea V; Margolin G; Elnitski L
    Epigenetics Chromatin; 2015; 8():14. PubMed ID: 25960768
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stability of the CpG island methylator phenotype during glioma progression and identification of methylated loci in secondary glioblastomas.
    Hill VK; Shinawi T; Ricketts CJ; Krex D; Schackert G; Bauer J; Wei W; Cruickshank G; Maher ER; Latif F
    BMC Cancer; 2014 Jul; 14():506. PubMed ID: 25012071
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comprehensive analysis of CpG island methylator phenotype (CIMP)-high, -low, and -negative colorectal cancers based on protein marker expression and molecular features.
    Zlobec I; Bihl M; Foerster A; Rufle A; Lugli A
    J Pathol; 2011 Nov; 225(3):336-43. PubMed ID: 21660972
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations.
    Ogino S; Kawasaki T; Kirkner GJ; Loda M; Fuchs CS
    J Mol Diagn; 2006 Nov; 8(5):582-8. PubMed ID: 17065427
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CpG island methylator phenotype is an independent predictor of survival after curative resection for colorectal cancer: A prospective cohort study.
    Kim CH; Huh JW; Kim HR; Kim YJ
    J Gastroenterol Hepatol; 2017 Aug; 32(8):1469-1474. PubMed ID: 28087988
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.